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Brain 11 was the 25th International Symposium 
on Cerebral Blood Flow, Metabolism and 
Function, and was organized by Anna Planas 
of Institut d’investigacions Biomèdiques August 
Pi i Sunyer (IDIBAPS) and colleagues on behalf 
of the International Society for Cerebral Blood 
Flow and Metabolism (ISCBFM). ISCBFM 
is an organization of scientists and physicians 
interested in the study of cerebral blood flow and 
metabolism, whose members come from all over 
the world. This meeting is held biennially, and 
attracts over 1000 scientists and physicians from 
40 different countries. The program included 
state-of-the-art topics, such as neurovascular 
biology, cell-based therapy, neuroimmunology 
and neuroimaging.
Neuron–blood vessel interactions
The meeting began with a plenary lecture 
given by Berislav V Zlokovic of the University 
of Rochester (NY, USA) who presented work 
demonstrating a previously unrecognized role 
of the cerebral vasculature and neurodegenera-
tion, with an emphasis on pericytes. The role 
of pericytes in the brain vasculature has only 
recently been shown to contribute significantly 
to neuro vascular functions. By studying mice 
deficient in pericytes, Zlokovic and colleagues 
found that this led to disruption of the BBB, 
with subsequent leakage of blood-derived neuro-
toxins [1]. Entry of neurotoxins then led to neu-
rodegeneration. These findings have important 
clinical implications because they suggest the 
importance of targeting the brain vasculature 
in the prevention of neurodegenerative disease.
The link between Alzhiemer’s disease and 
inflammation is often controversial, but lipo-
polysaccharide (LPS)-induced inflam mation 
appears to prevent the normal efflux of b-amy-
loid out of the brain, potentially leading to 
abnormal retention and accumulation.
Inflammation is known to negatively affect 
BBB integrity. Thus, anti-inflammatory strat-
egies could be neuroprotective by virtue of 
their salutary effects on the brain vasculature. 
Cannabinoids are known to be neuroprotective, 
and one mechanism of protection appears to be 
through anti-inflammatory properties [2]. LPS 
treatment increased cannabinoid receptor (CB2) 
expression, and CB2 agonists increased tight 
junction protein (TJP) expression and strength-
ened the BBB while preventing leukocyte adhe-
sion. This would suggest that a potential protec-
tive mechanism of cannabinoids is through an 
anti-inflammatory, BBB strengthening property.
Factors leading to BBB disruption were also 
discussed in other presentations. While past 
work has demonstrated the importance of matrix 
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metalloproteinase (MMP) activation in BBB disruption, repair 
mechanisms were also explored [3]. While TJPs disappear early after 
ischemic stroke, they reappear at 3 weeks in newborn vessels and 
even surrounding pericytes and astrocytes, and this was correlated 
to increased MMP-2 (astrocytes) and MMP-3 (pericytes). These 
observations suggest that MMPs, while acutely damaging to the 
BBB, may also be important in angiogenesis and BBB remodeling.
Restorative therapies
With the recognition that most patients do not present for medi-
cal attention until hours or sometimes days following stroke, 
efforts to understand how the brain recovers from cerebral isch-
emic insults and to identify potential therapeutic strategies have 
been the focus of this field for nearly a decade. With recent interest 
in the potential of stem cells to cure a variety of diseases, their 
application in brain ischemia is no exception. 
Cell-based therapy
The current status of cell-based therapy in stroke and related con-
ditions was reviewed. Both neuron-derived and bone marrow-
derived mesenchymal cells (MSCs) could be administered to 
laboratory animals subjected to various types of CNS insults [4,5] 
and new techniques that include antioxidant gene transfer to stem 
cells proved efficient for the survival of  stem cells [6]. These cells 
integrate into the brain and lead to improvement in long-term 
neurological function. Furthermore, cotreatment with trophic 
factors could improve the ability of stem cells to repair injury to 
the spinal cord. Advanced imaging techniques allow noninvasive 
nanoparticle labeling of the transplanted cells, and these studies 
were able to compare the efficiency of transplantation of bone 
marrow-derived MSCs when given peripherally or intracerebrally, 
with more efficient uptake occurring when given intracerebrally.
Human studies of cell-based therapies were also reviewed [7]. 
While the collective clinical experience is still in its infancy, a 
few anecdotal cases of remarkable functional improvement were 
shown. Most clinical studies are currently examining the role 
of MSCs, and the studies are at the Phase II level, where safety, 
rather than efficiacy, are being evaluated. While it was emphasized 
that cell-based therapy is still in the early stages of investigation 
and its precise role in the treatment of patients is unclear, many 
speakers seemed optimistic.
Endogenous CNS repair mechanisms & neurogenesis
CNS injury frequently leads to an inevitable and irreversible loss 
of function owing to the widely held notion that neurons, par-
ticularly in the adult brain, do not regenerate. However, recent 
work has shown that neurons are indeed capable of regenerating 
(‘neurogenesis’) in certain brain regions and under specific set-
tings. Thus, the possibility that brain cells can be restored through 
endogenous repair mechanisms opens up a host of therapeutic 
strategies to optimize this recently recognized property [8]. 
In one session, neuroscientists discussed novel applications of 
neurogenesis through the activation of endogenous neural stem 
cells (NSCs) and/or pharmacological pretreatment of NSCs 
prior to transplantation. Attempts to maximize the spread of 
neurogenesis after injury have yielded broad insights into the iden-
tification of specific molecules with neuroprotective properties. 
Several researchers presented new strategies for improving CNS 
repair during various insults. NSCs pretreated with drugs, such as 
minocycline, LPS and agmatine (an endogenous inhibitor of nitric 
oxide synthase), all attenuated infarct size and enhanced neurologi-
cal recovery when transplanted into the ischemic brains of rodents. 
Minocycline-treated NSCs subjected to ischemia-like insults 
in vitro followed by reperfusion deregulated several antioxidant 
genes and trophic factors, such as Nrf2, NADH quinone oxido-
reductase 1, HO, BDNF, NGF, GDNF and VEGF. A few investi-
gators also suggested that PI3k/Akt or Akt/JNK signaling path-
ways were associated with this neuroprotection. Preconditioning 
and other approaches aimed at enhancing NSC protection, such 
as transfection of transgenes, were also presented. Some studies 
explored the role of miRNAs that could regulate the expression 
of various genes. In one study, inhibiting miRNA (mir1), which 
binds to the 3´ UTR of the IGF-1 gene, could promote protection 
of NSCs, and lead to improved NSCs for transplantation. 
Inflammation in stroke
The role of inflammation in brain ischemia has been increasingly 
studied, and it is generally recognized that the acute inflammatory 
response negatively affects stroke outcome [9]. Several presenta-
tions characterized specific immune targets that could be manipu-
lated to improve outcome from experimental models. Studies of 
sphingosine kinase antagonists, the P2Y12 nucleotide receptor 
(and also the site at which the popular antiplatelet drug clopido-
grel acts), and agonists of cannabinoids/cannabinoid receptors, 
all showed salutary effects on brain cell survival and neurological 
outcome. A few presentations demonstrated that ischemic toler-
ance, or the phenomenon that sublethal stress leads to protection 
from a subsequent lethal insult, can be conferred by manipulating 
certain inflammatory pathways. These included the stimulation of 
toll-like receptor 3 (TLR3) or the sphingosine kinase-2. Ischemic 
preconditioning was also correlated to increases in endogenous 
anti-inflammatory factors, including agmatine.
The role of microglia in brain ischemia was also explored in 
a symposium that challenged the notion that microglia possess 
damaging functions in both acute and chronic neurological condi-
tions. While some microglial properties certainly appear to worsen 
outcome from brain ischemia, ablation of brain microglia in the 
adult brain led to worsening of ischemic outcome and alteration of 
the ischemic inflammatory response [10]. This worsening seemed 
to be related to the depletion of microglia-derived prosurvival 
factors, such as IGF-1 and galectin-3. However, the deletion of 
microglia from neonatal brains had no effect on stroke outcome 
and emphasizes clear differences in responses to ischemic insults 
in the developing versus adult brain. Other microglial functions 
appear vital to effective recovery. A newly characterized phagocytic 
receptor, triggering receptor expressed on myeloid cells (TREM-2), 
may be important in the removal of injured neurons, and its defi-
ciency could potentially negatively impact stroke outcome. The 
examination of microglia in aged human brain samples of subjects 
carrying a diagnosis of Alzheimer’s disease and related conditions 
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also revealed that during senescence, microglia show signs of degen-
eration and abnormal responses [11]. Furthermore, microglia show 
signs of damage prior to the development of tau pathology, and 
would suggest that treatments targeting microglia are unlikely to 
affect neurodegeneration in conditions such as Alzheimer’s disease.
Importance of the peripheral circulation
The peripheral circulation has been understudied in this field, but 
recent work presented at this meeting has emphasized its impor-
tance. The study of bone marrow cells in different stroke models 
revealed early immune activation in these cells. However, the stress 
of surgery and anesthesia appeared to contribute to some of these 
responses and these factors need to be considered when interpret-
ing animal stroke model results. Nevertheless, by utilizing a bone 
marrow chimeric approach, CD36 (an inflammatory mediator 
that contributes to ischemic worsening owing to elevated plasma 
cholesterol [12]) derived from circulating immune cells was shown 
to contribute to stroke worsening, rather than CD36 derived from 
the brain. At the clinical level, T-cell responses in acute stroke 
patients demonstrated a TH1 bias, while proteomic ana lysis of 
plasma samples from acute ischemic stroke patients revealed the 
presence of many proteins involved in inflammation and clotting.
Summary
Current research in the area of stroke and neurodegeneration 
were presented. Several meeting themes challenged prior concepts 
showing that vascular stress may precede neurodegeneration, and 
that microglia possess important prosurvival and protective func-
tions. The peripheral circulation and the status of cell-based and 
regenerative therapies were also reviewed.
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